Qitong Chen,Dengjie Ouyang,Munawar Anwar,Ning Xie,Shouman Wang,Peizhi Fan,Liyuan Qian,Gannong Chen,Enxiang Zhou,Lei Guo,Xiaowen Gu,Boni Ding,Xiaohong Yang,Liping Liu,Chao Deng,Zhi Xiao,Jing Li,Yunqi Wang,Shan Zeng,Jinhui Hu,Wei Zhou,Bo Qiu,Zhongming Wang,Jie Weng,Mingwen Liu,Yi Li,Tiegang Tang,Jianguo Wang,Hui Zhang,Bin Dai,Wuping Tang,Tao Wu,Maoliang Xiao,Xiantao Li,Hailong Liu,Lai Li,Wenjun Yi,Quchang Ouyang

Corrigendum: Progression-free survival and time to progression as potential surrogate endpoints for overall survival in chemoradiotherapy trials in limited-stage small-cell lung cancer: A systematic review and meta-analysis

Corrigendum: Effectiveness and Safety of Pyrotinib, and Association of Biomarker With Progression-Free Survival in Patients With HER2-Positive Metastatic Breast Cancer: A Real-World, Multicentre Analysis

Corrigendum to “Efficacy and Safety of First-Line Immunotherapy in Combination with Chemotherapy for Patients with Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis”

Corrigendum: Association of Dynamic Changes in Peripheral Blood Indexes With Response to PD-1 Inhibitor-Based Combination Therapy and Survival Among Patients With Advanced Non-Small Cell Lung Cancer

Corrigendum: Neoadjuvant Tislelizumab Combined with Chemotherapy in Locally Advanced Oral or Oropharyngeal Squamous Cell Carcinoma: a Real-World Retrospective Study.

Corrigendum: Anlotinib Combined With Anti-PD-1 Antibodies Therapy in Patients With Advanced Refractory Solid Tumors: A Single-Center, Observational, Prospective Study

Corrigendum: Brain Metastases from Esophageal Squamous Cell Carcinoma: Clinical Characteristics and Prognosis

Corrigendum: MRI radiomics predicts progression-free survival in prostate cancer

Corrigendum: Identification of Microtube-Associated Biomarkers in Diffuse Large B-cell Lymphoma and Prognosis Prediction.

Corrigendum: Anlotinib Combined with Chemoradiotherapy Exhibits Significant Therapeutic Efficacy in Esophageal Squamous Cell Carcinoma

Corrigendum: Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Predictors of Outcomes in Patients With Unresectable Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization Plus Sorafenib

Corrigendum: Chemoresistance and Metastasis in Breast Cancer Molecular Mechanisms and Novel Clinical Strategies

Corrigendum to “Treatment-Related Adverse Events Associated with HER2-Targeted Antibody-Drug Conjugates in Clinical Trials: a Systematic Review and Meta-Analysis” [eclinicalmedicine 55 (2022) 101795]

Corrigendum: the Significance of Transarterial Chemo(embolization) Combined with Tyrosine Kinase Inhibitors and Immune Check Point Inhibitors for Unresectable Hepatocellular Carcinoma in the Era of Systemic Therapy: A Systematic Review

Corrigendum: Clinical Significance and Immunometabolism Landscapes of a Novel Recurrence-Associated Lipid Metabolism Signature In Early-Stage Lung Adenocarcinoma: A Comprehensive Analysis

Corrigendum: Establishment and Validation of Prognostic Nomograms for Patients with Parotid Gland Adenocarcinoma Not Otherwise Specified: a SEER Analysis from 2004 to 2016.

Corrigendum to "the Role of 18F-FDG PET/CT and MRI in Assessing Pathological Complete Response to Neoadjuvant Chemotherapy in Patients with Breast Cancer: A Systematic Review and Meta-Analysis".

Corrigendum: LCN2 Is a Potential Biomarker for Radioresistance and Recurrence in Nasopharyngeal Carcinoma

Corrigendum to “system Analysis of ROS-Related Genes in the Prognosis, Immune Infiltration, and Drug Sensitivity in Hepatocellular Carcinoma”

Corrigendum: Correlation analysis of MRD positivity in patients with completely resected stage I-IIIA non-small cell lung cancer: a cohort study

Corrigendum: Comprehensive transcriptomic analysis of critical RNA regulation associated with metabolism and prognosis in clear cell renal carcinoma